Sunosi (solriamfetol) is officially classified as a nonstimulant wake-promoting agent by the FDA, even though it shares some properties with traditional stimulants. It works on the same brain chemicals as amphetamines, but through a narrower, less intense mechanism. The DEA placed it in Schedule IV of the Controlled Substances Act, the same category as modafinil and sleep medications like zolpidem, well below the Schedule II classification given to amphetamines and methylphenidate.
How Sunosi Works in the Brain
Sunosi blocks the reabsorption of two brain chemicals: dopamine and norepinephrine. By preventing these molecules from being recycled back into nerve cells, it increases their levels in the spaces between neurons. Higher dopamine and norepinephrine levels promote wakefulness and alertness.
This is where the comparison to stimulants gets interesting. Amphetamines do the same thing, blocking reabsorption of dopamine and norepinephrine. But amphetamines also force nerve cells to actively release extra dopamine and norepinephrine into the brain, essentially flooding the system. Sunosi does not trigger this release. It only prevents what’s already circulating from being cleaned up as quickly. That distinction matters because the forced-release effect of amphetamines is what drives much of their euphoria, cardiovascular strain, and abuse potential.
Sunosi also has a notably clean profile in terms of what it doesn’t touch. It has no significant effect on serotonin, and it doesn’t interact with histamine receptors, nicotine receptors, GABA receptors, or the enzymes that break down mood-related brain chemicals. Traditional stimulants tend to cast a wider net across these systems, which is partly why they carry more side effects.
What Sunosi Is Approved to Treat
The FDA approved Sunosi to improve wakefulness in adults with excessive daytime sleepiness caused by narcolepsy or obstructive sleep apnea (OSA). For narcolepsy, the typical starting dose is 75 mg once daily, with a maximum of 150 mg. For sleep apnea, the starting dose is lower at 37.5 mg, also with a 150 mg ceiling. Both are taken in the morning.
An important distinction for sleep apnea patients: Sunosi does not treat the airway obstruction itself. It’s meant to address the leftover daytime drowsiness that persists even when you’re using a CPAP machine or other treatment. You need to have been on your primary airway treatment for at least a month before starting Sunosi, and you continue that treatment alongside it.
How It Compares to Modafinil and Amphetamines
Sunosi falls into the same FDA category as modafinil (Provigil) and armodafinil (Nuvigil): nonstimulant wake-promoting agents. All three sit in Schedule IV and are taken as a single morning dose. Traditional stimulants like amphetamine and methylphenidate, by contrast, are Schedule II drugs with significantly higher abuse potential and a broader range of cardiovascular and psychiatric side effects.
In an indirect comparison study published in the Journal of Clinical Sleep Medicine, Sunosi at 150 mg outperformed both modafinil and armodafinil on standard measures of wakefulness and sleepiness after 12 weeks of treatment in people with obstructive sleep apnea. Both the ability to stay awake during testing and self-reported sleepiness scores favored Sunosi. The safety profiles across all three medications were similar. One area where Sunosi didn’t pull ahead was in measures of daily functioning, where results were comparable to modafinil.
Abuse Potential
Because Sunosi affects dopamine, the brain chemical most associated with reward and addiction, the question of abuse potential is reasonable. A dedicated study compared how much participants “liked” Sunosi at various doses against phentermine (a stimulant appetite suppressant) and placebo.
At every dose tested, Sunosi produced more “liking” than placebo but significantly less than phentermine. Participants were also less willing to take Sunosi again compared to phentermine. Notably, at higher experimental doses (well above the prescribed range), Sunosi actually produced more negative effects like anxiety and agitation rather than increasing euphoria. This ceiling on pleasurable effects is one reason the DEA placed it in Schedule IV rather than a higher category.
That said, Schedule IV still means it has some potential for dependence, and prescriptions are tracked accordingly. It’s a controlled substance, just a lower-risk one compared to classic stimulants.
Why the Label Matters
The “is it a stimulant” question comes up often because the answer affects practical things: how your prescription is handled, how often you need refills and office visits, whether it shows up on workplace drug screenings, and what your insurance requires for coverage. Schedule IV medications generally involve fewer prescribing restrictions than Schedule II stimulants. You may find it easier to get refills, and some insurance plans have lower prior authorization hurdles.
Pharmacologically, Sunosi lives in a gray zone. It boosts the same brain chemicals as stimulants, and you’ll feel more awake and alert on it, which is the whole point. But its mechanism is more targeted, its abuse profile is lower, and its regulatory classification reflects that. Calling it a stimulant isn’t technically accurate based on how the FDA and DEA categorize it, but saying it has “stimulant-like” properties is fair.